Although ortho-phthalaldehyde (OPA) has been recommended as an alternative to glutaraldehyde for the sterilization and disinfection of heat-sensitive medical equipment, its toxicity has not been thoroughly investigated. The present study was designed to evaluate the dermal irritation and sensitization potential of OPA. Results of the Epiderm Skin Irritation Test identified OPA as a dermal irritant and furthermore, demonstrated that OPA is a more potent skin irritant than glutaraldehyde. Consistent with the in vitro results, exposure to 0.75% OPA induced irritancy when evaluated in a combined irritancy local lymph node assay (LLNA) exposed to 0.75% OPA. A concentration-dependant increase in lymphocyte proliferation was observed after OPA exposure with a calculated EC3 value of 0.051%, classifying this chemical as an extreme sensitizer. IgE-inducing potential was evaluated by phenotypic analysis of draining lymph node cells and measurement of total and OPAspecific serum IgE levels in the mice. The 0.1% and 0.75% exposed groups yielded significant increases in the IgE+B220+ cell population in the lymph nodes while only the 0.75% exposed group demonstrated significant increases in IL-4 mRNA in the draining lymph nodes and total and OPA specific serum IgE levels. A significant elevation in OPA-specific IgG1 was also observed after exposure to 0.75% OPA. These results demonstrated the dermal irritation and sensitization potential of OPA in an animal model raising concern about the skin irritation and sensitization potential of OPA among healthcare workers who are potentially exposed to the chemical.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.